Given that AR has been shown to regulate the expression of ERα target genes in ERα-negative breast cancer (35), it will be interesting to determine the potential importance of LRH-1 in the regulation of ERα target genes in endocrine resistant breast cancer and/or in ERα-negative breast cancer and consequently its therapeutic potential in breast cancer subtypes currently lacking targeted therapies. The gene discussed is AR; the disease is breast carcinoma.